•  
  •  
  •  
  •  

2026-08-12 20:17:19

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  Canada

Stock Report

  • Collaboration framework between the Petroleum Technology Research Centre, Canada and Oil India Ltd
  • 37 Canadian Financial Institutions, part of NDBWG, select Intellect to Drive Digital Banking Transformation
  • OneSource Supports Second Generic Semaglutide Approval in Canada
  • CuraTeQ Biologics Secures Health Canada NOC for Bevqolva™ Bevacizumab Biosimilar
  • OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection
  • Khalsa Credit Union, BC, Canada selects Intellect to power its next-generation digital banking platform
  • Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™, Biosimilars to Prolia® and Xgeva®
  • Green Graphite Technologies Delivers Project with Rain Carbon Canada to Advance Production of High-Purity Graphite for Lithium-Ion Batteries
  • Delhivery International Launches Economy Air Shipping to UK, Canada, and Australia
  • Centum Electronics sharpens strategic focus and realigns Global Portfolio
  • Intellect Secures Purple Fabric-Powered Governance, Risk & Compliance AI Mandate in Canada with Carte Wealth
  • Northern Graphite and Rain Carbon Announce R&D Grant to Develop Sustainable Battery Anode Materials
  • Zydus receives approval from Health Canada for Mesalamine suppositories
  • Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V., a Biosimilar to Stelara®
  • Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
  • Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 & 1 mg
  • Biocon Biologics receives Health Canada approval for Yesafili™
  • Piramal Pharma Ltd completes USFDA inspection of Aurora facility with Zero Form-483 observations
  • InfoBeans to drive AI-powered transformation for one of Canada's largest Standards Developing Organization
  • USFDA Inspection at Jubilant HollisterStier General Partnership's Contract manufacturing facility at Montreal, Canada
  • Mini Diamonds India Ltd enters into business with Parasamani Inc., Canada
  • Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®
  • BLS International again wins the Contract with the High Commission of India in Canada
  • Sun Pharma Canada Launches PRWINLEVI® - clascoterone cream 1% w/w, a Novel Topical Treatment for Acne

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025